Myra Solano Garcia, who has Alzheimer's, says the drug Kisunla may be one reason she can still drive, cook, and sing.

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

The Food and Drug Administration approved the drug, now marketed as Kisunla, in July of 2024. It's one of two drugs approved since 2023 that can clear the brain of sticky amyloid plaques ...